Paul Hagedoorn

The clinical relevance of dry powder inhaler performance for drug delivery

Pascal Demoly, Paul Hagedoorn, Anne H. de Boer et al. · Respiratory Medicine · 2014 · 150 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +16

Characterization of inhalation aerosols: a critical evaluation of cascade impactor analysis and laser diffraction technique

Anne H. de Boer, Doetie Gjaltema, Paul Hagedoorn et al. · International Journal of Pharmaceutics · 2002 · 145 citations

Natural Sciences, Toxicology, Atmospheric Chemistry +16

Air classifier technology (ACT) in dry powder inhalationPart 1. Introduction of a novel force distribution concept (FDC) explaining the performance of a basic air classifier on adhesive mixtures

A DEBOER, Paul Hagedoorn, Doetie Gjaltema et al. · International Journal of Pharmaceutics · 2003 · 113 citations

Pharmacy, Materials Science, Mechanical Engineering +8

Can ‘extrafine’ dry powder aerosols improve lung deposition?

Anne H. de Boer, Doetie Gjaltema, Paul Hagedoorn et al. · European Journal of Pharmaceutics and Biopharmaceutics · 2015 · 88 citations · Full text

Pharmacy, Respiratory Therapy, Drug Delivery +16

Inhalation characteristics and their effects on in vitro drug delivery from dry powder inhalers Part 2: Effect of peak flow rate (PIFR) and inspiration time on the in vitro drug release from three different types of commercial dry powder inhalers

A DEBOER, Doetie Gjaltema, Paul Hagedoorn · International Journal of Pharmaceutics · 1996 · 88 citations

Pharmacy, Pharmacokinetics, Pharmacology +17